News | September 24, 2021
Novavax and Serum seek WHO approval for Covid-19 vaccine
It is a recombinant nanoparticle protein-based vaccine
It is a recombinant nanoparticle protein-based vaccine
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
The module offers the first preclinical laboratory information system of its kind that is fully integrated into the digital pathology workflow and provides efficient pathological studies of whole slides
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Subscribe To Our Newsletter & Stay Updated
